Court Documents: Manufacturers' Internal Memos pt 1

[Guest guest]

** Court Documents of Manufacturers’ Internal Memos

- scanned but not corrected - possibly from the Catch files. **

Court Documents: Manufacturers' Internal Memos

COURT DOCUMENTS: MANUFACTURERS' INTERNAL MEMOS DOCUMENTING:

"THE CORPORATE SYNDICATE BREAST IMPLANT POISONING COVER-UP"

Court Documents of Dow Chemical, Dow Corning, Bristol Myers, Minnesota

Mining and Manufacturing, and Heyer-Schulte Hot Memos:

This is a just a few of the thousands of court documents of corporate

interoffice memos written and circulated by the breast implant manufactures

and suppliers. If you are in possession of any other documents, please

forward them, and they will be added. We will let the public see for

themselves that this "poisoning" was foreseeable and deliberate and that

they fractured the lives of hundreds of thousands of humans for Billions

upon Billions of dollars. These Memos are taken directly from the court

documents. Below are Breast Implant Manufacturer's internal memos and

letters which were "uncovered" and presented as Court Exhibits. DOW

CORNING: DCC (Dow Chemical Company) and DCW (Dow Corning ).

Document. #1: Produced by DCC and DCW: (M-440097): Exhibit #29

This document from 1961 shows that Dr. Cronin, one of the doctors

credited with inventing silicone breast implants, was advised by The Dow

Corning Center for Aid to Medical Research that silicones would "bleed

through the envelope," and that it would migrate within the body. Gel bleed

and migration expose the body’s tissues to silicone, causing systemic

injury. Thus, the inventor and Dow knew of the bleed problem before

implants were ever marketed. (See Patents.).

January 24, 1961

Dr. D. Cronin

University Professional Buildings

6615 Street

Houston, Texas

Dear Dr. Cronin:

Since I am now associated with the Dow Corning Center for Aid to Medical

Research, Mr. Braley has asked me to answer your letter of January 9.

Although the silicones are inert in the body, an attempt to place silicone

fluids permanently in the body would lead to other problems. If injected

directly into the body, the fluids will not remain in the desired location.

A discussion of this problem is found in the enclosed paper "Toxicology of

the Silicones." If enclosed within a silicone bag, the fluids would tend to

diffuse out through the walls of the silicone rubber and be absorbed into

the tissues.

Yours very truly,

Mrs. Ethel Mullison, Staff Associate

DOW CORNING (Continued)

Document #2: Submitted by DCC & amp; DCW: (M3354): PROPRIETARY Exhibit #53

Document # 2 is a letter, from 1968, to the Dow Corning Toxicology

Department which shows the widespread distribution of 360 fluid, the fluid

used in silicone breast implants. It reveals that there was widespread

distribution in test dogs, and that the fate and chemical nature of silicone

after it "vacates the injection site was unknown."

October 9, 1968

Dr. Riffkin

Parenteral Formulations Section

The Squibb Institute for Medical Research New Brunswick, New Jersey 08903

Dear Dr. Riffkin:

I have been asked to answer your letter of September 18, 1968, to our Mr. E.

E. Frisch regarding the distribution and fate of injected silicones.

Enclosed you will find a report entitled "Studies of the Effects of Injected

Dow Corning 360 Fluid, 350 cc., in Dogs". This study was carried out using

C14 labeled DC 360 Fluid in order to determine the distribution of such a

polymer upon parentaral administration. The results of this study indicate

that distribution occurs throughout the entire body with no pronounced

concentration in any specific organ. It is evident by preliminary nature of

this study that the fate and chemical nature of the subject material after

it vacates the injection site is unknown.

I have also enclosed a copy of “Toxicology of Certain Silicones Fluids†by

R. R. McGregor as per your request.

Sincerely, E. J. Hobbs, Toxicologist, Toxicology Department

bcc: D. R. , E. E. Frison, M. J. Hunter, J. A. McHard

DOW CORNING (Continued)

Document #3 and Document #4: (M540060 and M-540061

and M-540062)

Produced by DCC and DCW

Mammary Task Force Minutes: Exhibit 106

These two (2) documents (Document #3 and Document #4), from May 12, 1975,

reveal that Dow was receiving reports from the field about significant

silicone bleed from implants. Bleed problems were pronounced when implants

were handled or flexed, as would be expected when implanted in a woman's

body. Document #3: Produced by DCC & amp; DCW: (M-540061 and M-540062)

Mammary Task Force:

A. Abbott, J. Boone, T. Brodhagen,F. Dennett, A. Rathjen, R. Garrett,D.

Houle, J. Hoyt, W. Larson, C. Leach, A Berg, P Meads, M. , K.

Polmanteer, S. s, B. Ringey, G. on, T. Salisbury, F. Stark,T.

Talcott, J. :

The question of bleed from our product was brought up. In Vancouver, and

elsewhere on the West Coast introduction, it was noted that after the

mammaries had been handled for awhile, the surface became oily. Also, some

were bleeding on the velvet in the showcase.

Get samples from production, and West Coast samples already shipped, and see

if something can be done about this. Also, samples from Heyer Schulte and

McGhan should be checked if possible. : Draw up the orientation

bars for both LP and Std. contours. Also, optimize needles for filling

mammaries to prevent large holes: trocars and other points. Dave in

TSD is also working on the filling problem.

Salisbury: New data sheet for all products to be available in

September......this can also be used to look at color and bleed with

age.....with the changes in the plastic surgery business that are happening

RIGHT NOW (Heyer Schulte, McGhan Medial, etc.), it was felt that aggressive

development and marketing activity in the next four months will make a

tremendous difference in Dow Corning's position in this market. The time to

act is NOW. AB/aa DOW CORNING (Continued)

Document #4: Produced by DCC & amp; DCW: (M-570062)

May 13, 1975

TO: Wil Larson,

cc: Tom Salisbury, Ann Berg, Art Rathjen, Forrest Stark, Jim ,

Tom Brodhagen

FROM: Tom Talcott

SUBJECT: (Bleed of Mammary Prosthesis - Task Group Action)

We are hearing complaints from the field about the demonstration samples

they are receiving. The general claim is that the units bleed profusely

after they have been flexed vigorously.

Tom

TDT/aca

DOW CORNING (Continued)

Document #5: Produced by DCC & amp; DCW: (M-19043): Exhibit #161 This

document, from March, 1977 is the infamous "crossed fingers" memo in which a

Dow employee states the he responded to plastic surgeons at an International

Society of Plastic Surgeons meeting as follows: “I assured them, with

crossed fingers, that Dow Corning too had an active "contracture/gel

migration" study underway.

Levier, Becker, Lentz, Oppelt, Fisch, Kelley, s, Carlyle, Hoyt

FROM: C. Leach - CO2322

Bob, a year ago before you joined the Implant Products PMS, Pat Walters was

assigned the task of researching subject phenomenon and recommending a

course of action for Dow Corning. This he did. As best I can tell we have

not taken significant action on any of his recommendations and except for a

"half-hearted low priority program" through Dr. Kaminski at

Northwestern University. We have done little in the past year. At the

recent Tahao Meeting of the International Society of Clinical Plastic

Surgeons, both McGhan and Medical Engineering did an excellent job of

merchandising their respective programs designed to shed light on this

issue.

Dr. Bob of McGhan detailed how he has devoted full time the past six months

in establishing programs to study capsular tissue with the Plastic Surgeons

across the country.

Several of our customers, looking to us as leaders in the industry, asked me

what we were doing. I assured them, with "crossed fingers," that Dow

Corning too had an active "contracture/gel migration" study underway. This

apparently satisfied them for the moment, but one of these days they will be

asking us for the results of our studies.

Beyond the mammaries and contracture. Dr. Swanson recently has been urging

that appropriate studies be undertaken to determine the potential for

migration of silicones elastomers particles throughout the body. Dr.

Hiebauer continues to publicly discuss the migration of such particles in

his monkeys and it is very likely just a matter of time until the orthopedic

community will be aggressively asking similar questions to those we are now

hearing from the Plastic Surgeons.

I am not sure where this unrest is leading, but suspect that our PMG, as the

steward of Dow Corning’s implantable products, should not be to comfortable

with our current lack of focus and co-ordinated leadership relating to this

entire issue. I suggest that this question be addressed at our next PMG

Meeting and clear definition given as to what answers we can reasonably be

expected to have as a manufacturer of implantable silicone materials, what

answers we do have, and what steps need to be taken to fill whatever gaps

that may exist in our needed storeroom of knowledge. In my opinion, the

black clouds are ominous and should be given more attention.

Cl Enc.

DOW CORNING (Continued)

Document #6: Produced by DCC & amp; DCW: CM-001134: Exhibit 173

The letter is from Dr. ph Connelly to Boley, Head of Biomaterial

Safety for Dow Corning, inquiring about any possible link between lupus and

silicone implants. Boley replies that Dow had performed “extensive safety

testing,†and that it is highly improbable that the symptoms of Dr.

Connelly’s patient could be linked to implants. Now, compare this statement

by Boley to his statement concerning safety in Document #7,which follows

Document #6 below.

January 22, 1980

Dow Corning

P. O. Box 100

Arlington, Texas 38002

Dear Sir,

This letter is in reference to the silastic breast implants.

The patient is under the care of her family doctor and has been feeling

poorly, and he has run a medical workup on her and had come up with some

tests which he says are suggestive of chronic lupus erythemoses. The

patient has come to me asking if there is any possibility of the prostheses

producing such changes.

I told her that the material used in the prostheses is very inert. However,

I was requested by her and by her family physician to contact you regarding

this, and I would appreciate any information you would be able to give me?

With kindest regards, I remain,

Sincerely,

ph R. Connelly, M. D.

Document #7: Produced by DCC and Dow Corning :

CM-001135

Compare this letter, by Boley, in 1983, to his reply to Dr. Connelly

in Document #6.

This 1983 Boley letter, which went to top Dow management, states that "we

have no valid long-term implant data to substantiate the safety of gels for

long-term use." Obviously, Boley lied to Dr. Connelly in 1980. The

admission that there was no data to substantiate silicone implant safety was

made 21 years after breast implants were put on the market.

April 23, 1980

ph R. Connelly, M.D.

2828 Main Street

Buffalo, N.Y.

Dear Dr. Connelly:

Please excuse the delay in responding to your letter of January 22, 1980.

Dow Corning, which you addressed your letter to, is only a marketing

arm for Dow Corning’s plastic surgery products. It appears that the

marketing people were uncomfortable in responding to your question and were

uncertain as to who should respond.

Dow Corning has performed extensive safety testing, in animals, on the

silicone materials from which SILASTIC breast implants are made. Based on

these tests the materials used in the implants have been judged safe. I

have also reviewed our product complaint files. Your inquiry appears to be

the first Dow Corning has received asking whether a silicone breast implant

could be a causative agent for chronic lupus erythematoses.

The data Dow Corning has suggests that it would be highly improbably that

your patient's symptom of chronic lupus erythematoses could be attributed to

the silicone breast implants.

Sincerely yours,

F. Boley

Senior Group Leader

Health Care Group Research

WFB:ld

MINNESOTA MINING AND MANUFACTURING:

Document #8: Produced by Minnesota Mining and Manufacturing:

MMM000000954 and MM000000955: Exhibit 198:

Compare the statements below by Minnesota Mining and Manufacturing to the

"DCC's Broley statement above in Document #6 and Document #7. Then, compare the Minnesota Mining and Manufacturing Patent # 4,455,691, by Van Aken

Redinger and A. Compton, both of Santa Barbara, California,

Assignee: Minnesota Mining and Manufacturing Company, St. , Minnesota -

which was filed October 3, 1979, citing the fallacies of Dow Corning's,

Polmanteer' Patent #4,138,382, granted by the Patent Office on

February 2, 1979.

**************Recession-proof vacation ideas. Find free things to do in the U.S. (http://travel.aol.com/travel-ideas/domestic/national-tourism-week?ncid=emlcntustrav00000002)